Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 34,578 shares, a drop of 41.3% from the November 30th total of 58,925 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily volume of 100,933 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 100,933 shares, the short-interest ratio is currently 0.3 days. Approximately 0.6% of the company’s shares are sold short.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Marc Duey bought 21,459 shares of the company’s stock in a transaction that occurred on Wednesday, December 10th. The stock was purchased at an average price of $1.17 per share, with a total value of $25,107.03. Following the transaction, the director owned 256,155 shares in the company, valued at $299,701.35. This trade represents a 9.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.63% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on APRE shares. HC Wainwright cut their price target on Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Aprea Therapeutics Trading Up 3.0%

NASDAQ:APRE traded up $0.03 during mid-day trading on Friday, hitting $0.98. The stock had a trading volume of 22,781 shares, compared to its average volume of 69,591. Aprea Therapeutics has a 52 week low of $0.90 and a 52 week high of $5.00. The stock has a market capitalization of $6.86 million, a price-to-earnings ratio of -0.46 and a beta of 1.23. The company has a 50 day simple moving average of $1.18 and a 200-day simple moving average of $1.48.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The firm had revenue of $0.00 million for the quarter. As a group, equities research analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current year.

About Aprea Therapeutics

Aprea Therapeutics is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.